Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.69 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.69 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | CDK1 | P06493 | 1/20 | 0.69 |
| ▸ | CDK4 | P11802 | 1/20 | 0.69 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.69 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.69 |
| ▸ | CCND1 | P24385 | 1/20 | 0.69 |
| ▸ | CDK7 | P50613 | 1/20 | 0.69 |
| ▸ | CDK9 | P50750 | 1/20 | 0.69 |
| ▸ | CCNH | P51946 | 1/20 | 0.69 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.69 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | ATG4B | Q9Y4P1 | 10/20 | 0.61 |
| ▸ | GSK3A | P49840 | 2/20 | 0.61 |
| ▸ | GSK3B | P49841 | 2/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283555 | 0.89 | ATG4B (0.62) | CDK2CDK5CCNE1CCNT1ALDH1A1 | |
| SCHEMBL6287963 | 0.88 | CDK2 (0.61) | CDK2CDK5CCNE1CCNT1ALDH1A1 | |
| SCHEMBL6286739 | 0.88 | ATG4B (0.64) | CDK2CDK5CCNE1CCNT1ALDH1A1 | |
| SCHEMBL6285422 | 0.88 | ATG4B (0.63) | CDK2CDK5CCNE1CCNT1ALDH1A1 | |
| SCHEMBL6286130 | 0.88 | ATG4B (0.63) | CDK2CDK5CCNE1CCNT1ALDH1A1 | |
| SCHEMBL6287944 | 0.86 | ATG4B (0.66) | CDK2CDK5CCNE1CCNT1ALDH1A1 | |
| SCHEMBL6278437 | 0.85 | GSK3B (0.66) | CDK2CDK5CCNE1CCNT1ALDH1A1 | |
| SCHEMBL6279160 | 0.85 | CDK2 (0.53) | CDK2CDK5CCNE1CCNT1ALDH1A1 | |
| SCHEMBL6285945 | 0.85 | CCNE1 (0.62) | CDK2CDK5CCNE1CCNT1ALDH1A1 | |
| SCHEMBL6288035 | 0.84 | CDK2 (0.52) | CDK2CDK5CCNE1CCNT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | claimed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | claimed |
| US-6863647-B2 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2005-03-08 | — | — | US | disclosed |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | disclosed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | CDK2 3/4885CDK5 129/4885CCNE1 83/4885 |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | CDK2 3/4885CDK5 129/4885CCNE1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.